The company said worldwide sales for the quarter Q1 2025 were $15,529 million, down 2% from the first quarter of the prior year, or up 1% excluding the impact of foreign exchange. KEYTRUDA sales grew 4% to $7,205 million.

1. 01

   The company said worldwide sales for the quarter Q1 2025 were $15,529 million, down 2% from the first quarter of the prior year, or up 1% excluding the impact of foreign exchange. KEYTRUDA sales grew 4% to $7,205 million.

2. 02

   Merck said GARDASIL/GARDASIL 9 sales for Q1 fell 41% to $1,327 million, citing lower demand in China as the main factor. WINREVAIR sales were $280 million.

3. 03

   The company said GAAP diluted EPS was $2.01 and non-GAAP EPS was $2.22 for Q1 2025. It also said GAAP and non-GAAP EPS for Q1 2024 included a charge of $0.26 per share related to the acquisition of Harpoon.

4. 04

   The company maintained its full-year sales outlook of $64.1 billion to $65.6 billion and said its new non-GAAP EPS outlook is $8.82 to $8.97, versus the prior $8.88 to $9.03. The company said the outlook reflects a one-time charge of about $0.06 per share related to Hengrui Pharma.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.